Cryoport, Inc. CYRX
20.56 USD -0.18 (-0.87%)
At closeNov 12, 2026, 5:00 AM EST
20.40 -0.16 -0.78%
Pre-market · Nov 12, 5:00 AM ET
20.47 Day range 21.78
7.61 52-week range 21.78
- YTD
- +114.17%
- 1 year
- +132.32%
News
defenseworld.net 93,646 CryoPort, Inc. $CYRX Shares Sold by CenterBook Partners LP CenterBook Partners LP lessened its stake in shares of CryoPort, Inc. (NASDAQ: CYRX) by 54.6% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
seekingalpha.com Cryoport Needs To Chill Down (Downgrade) Cryoport, Inc. is downgraded from Hold to Sell due to valuation concerns despite strong revenue growth. CYRX's balance sheet improved after the CRYOPDP sale, with net cash of $204.8 million, but…
seekingalpha.com Cryoport, Inc. (CYRX) Q3 2026 Earnings Call Transcript Cryoport, Inc. ( CYRX ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Jerrell Shelton - Chairman, President & CEO Robert Stefanovich - Senior VP, CFO, Treasurer & Chief…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
benzinga.com Keybanc Maintains Overweight on CryoPort, Raises Price Target to $20 Keybanc analyst Paul Knight maintains CryoPort (NASDAQ:CYRX) with a Overweight and raises the price target from $17 to $20.
benzinga.com Needham Maintains Buy on CryoPort, Raises Price Target to $28 Needham analyst David Saxon maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $19 to $28.
marketbeat.com CryoPort Q3 Earnings Call Highlights CryoPort NASDAQ: CYRX raised its full-year 2026 revenue outlook after reporting third-quarter revenue growth of 14%, supported by demand for its cell and gene therapy services and cryogenic products.
zacks.com CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.
benzinga.com CryoPort Q3 2026 Earnings Call Transcript CryoPort (NASDAQ:CYRX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com CryoPort Raises FY2026 Sales Guidance from $192.000M-$196.000M to $197.000M-$199.000M vs $195.441M Est CryoPort (NASDAQ:CYRX) raises FY2026 sales outlook from $192.000 million-$196.000 million to $197.000 million-$199.000 million vs $195.441 million estimate.- benzinga.com CryoPort Q3 EPS $(0.25) Misses $(0.18) Estimate, Sales $50.220M Beat $48.828M Estimate CryoPort (NASDAQ:CYRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 38.89 percent decrease over losses of $(0.18)…
prnewswire.com Cryoport Reports Third Quarter 2026 Financial Results Third quarter revenue grew 14% year-over-year to $50.2 million Commercial Cell and Gene Therapy revenue increased 20% year-over-year Supporting a record 788 global clinical trials and 23 commercially…
benzinga.com CryoPort Q2 2026 Earnings Call Transcript CryoPort (NASDAQ:CYRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time…- benzinga.com BTIG Maintains Buy on CryoPort, Raises Price Target to $26 BTIG analyst David Larsen maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $25 to $26.